Meta-Analysis Shows No SSI Difference Between Chlorhexidine and Povidone Iodine for Vaginal Antisepsis
This systematic review and meta-analysis examined vaginal antisepsis practices in patients undergoing major gynecologic operations. The study included 9538 patients and compared chlorhexidine gluconate with povidone iodine. The primary outcome assessed was the rate of surgical site infections. Secondary outcomes included urinary tract infections and vaginal irritation.
The analysis found no statistically significant difference in surgical site infections between the two agents. The relative risk was 1.20 with a 95% CI of 0.92-1.57 based on data from 9538 patients. Consequently, the form of vaginal antisepsis can be used for SSI prevention according to current guidelines supported by these findings.
However, urinary tract infections showed a significantly higher risk for chlorhexidine gluconate. The relative risk was 1.48 with a 95% CI of 1.03-2.14 in a subset of 6061 patients. Vaginal irritation was noted as an adverse event. The authors note that further randomized studies are needed to support findings regarding UTIs.
Practice relevance is tempered by the need for additional research on infection risks. The certainty of the evidence regarding urinary tract infections remains uncertain. Clinicians should weigh the lack of SSI benefit against the potential increase in UTIs when selecting an agent.